Skip to main content
Peter Luo, MD, Internal Medicine, Harrisburg, PA

PeterXingyuLuoMD

Internal Medicine Harrisburg, PA

Hospital Medicine/Hospitalist

Physician

Are you Dr. Luo?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 10 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    111 S Front St
    Harrisburg, PA 17101
    Phone+1 717-231-8772
    Fax+1 717-231-8435

Summary

  • Dr. Peter Luo, MD is a board certified internist in Harrisburg, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, Delaware, and Maryland. He is affiliated with UPMC Harrisburg, UPMC Pinnacle Community Osteopathic, and Christiana Care - Wilmington Hospital.

Education & Training

  • Boston University School of Medicine
    Boston University School of MedicineClass of 2010

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2022 - 2026
  • DE State Medical License
    DE State Medical License 2022 - 2025
  • PA State Medical License
    PA State Medical License 2013 - 2022
  • American Board of Internal Medicine Internal Medicine

Press Mentions

  • Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
    Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.January 19th, 2022
  • Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
    Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ ProgramMarch 16th, 2021
  • Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
    Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy ProfilesFebruary 1st, 2021
  • Join now to see all